SOUTH SAN FRANCISCO, CA, Cellares, dedicated to clinical and industrial-scale cell therapy manufacturing, announced a $255 million Series C funding round.
Cellares, dedicated to clinical and industrial-scale cell therapy manufacturing, announced a $255 million Series C funding round led by Koch Disruptive Technologies, with participation from Bristol Myers Squibb, DFJ Growth, Willett Advisors, Eclipse, Decheng Capital, and 8VC.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
